Results 141 to 150 of about 5,058,773 (393)

A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma

Cell Reports Medicine
Summary: Cisplatin is a cornerstone chemotherapy for nasopharyngeal carcinoma (NPC); however, certain patients are ineligible for cisplatin-based regimens.
Xiong Zou, Xi Ding, Zheng-Kai Feng, Yan-Feng Ouyang, Hui-Feng Li, Kai Wen, Zhi-Qiang Wang, You-Ping Liu, Yong-Long Liu, Wei-Jing Zhang, Qi Yang, Si-Yuan Chen, Yu-Long Xie, Ruo-Qi Xie, Chao Lin, Chen-Mei Gu, Pei-Yu Huang, Rui Sun, Yi-Jun Hua, Rui You, Ming-Yuan Chen   +20 more
doaj   +1 more source

Prospective observational study of carbon‐ion radiotherapy for non‐squamous cell carcinoma of the head and neck [PDF]

, 2017
Katsuyuki Shirai, Jun‐ichi Saitoh, Atsushi Musha, Takanori Abe, Daijiro Kobayashi, Takéo Takahashi, Tomoaki Tamaki, Hidemasa Kawamura, Yukihiro Takayasu, Masato Shino, Minoru Toyoda, Katsumasa Takahashi, Junko Hirato, Satoshi Yokoo, Kazuaki Chikamatsu, Tatsuya Ohno, Tatsuya Nakano, the Working Group on Head and Neck Tumors   +17 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

An ontology for carcinoma classification for clinical bioinformatics [PDF]

, 2005
There are a number of existing classifications and staging schemes for carcinomas, one of the most frequently used being the TNM classification.
Kumar, Anand, Marwede, Dirk, Novotny, Daniel, Smith, Barry, Yip, Yum Lina   +4 more
core  

Characterization of Androgen Receptor Complex Associated Protein (ARCAP) in hepatocellular carcinoma and liver

, 2021
Tai-Jay Chang, Cheng-Yuan Hsia, Gar-Yang Chau, Liang-Tsai Hsiao, Kuang-Tzu Huang, Kung-Liang King, Wing-Yiu Lui, Anna F.-Y. Li, Chia-Lin Wang, Pin-Hsing Tsai, Yueh Chien, Ta-Hsien Lin   +11 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Functional evaluation of hepatic parenchyma with dynamic tests (Indocyanine green and Hippurate ratio) in patients with HCC [PDF]

, 2011
Our aim was to assess hepatic functionality in patients with HCC and candidate for liver resection. We used dynamic tests of liver functionality Indocyanine green (ICG) and Hippurate ratio, for the evaluation of surgical risk and postoperative clinical
PETRACCIA, LUISA
core  

Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma [PDF]

, 2012
Li‐Chun Lu, Yu‐Yun Shao, Kuo‐Hsing Chen, Zhong‐Zhe Lin, Yi‐Chun Yeh, Wen‐Yi Shau, Chih‐Hung Hsu, Ann‐Lii Cheng, Mei‐Shu Lai   +8 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source